266
Participants
Start Date
February 6, 2015
Primary Completion Date
October 10, 2018
Study Completion Date
July 19, 2022
OLAPARIB
300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
Single agent chemotherapy
Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Leuven
Research Site, Miskolc
Research Site, Debrecen
Research Site, Córdoba
Research Site, México
Research Site, Ghent
Research Site, Győr
Research Site, Goyang-si
Research Site, Mineola
Research Site, Albany
Research Site, Córdoba
Research Site, Girona
Research Site, Granada
Research Site, Afula
Research Site, Abington
Research Site, Milan
Research Site, Milan
Research Site, Milan
Research Site, Towson
Research Site, Chapel Hill
Research Site, Madrid
Research Site, Madrid
Research Site, Fort Gordon
Research Site, Haifa
Research Site, Birmingham
Research Site, Mobile
Research Site, Nashville
Research Site, Knoxville
Research Site, Columbus
Research Site, Meldola
Research Site, Detroit
Research Site, Ramat Gan
Research Site, Tel Litwinsky
Research Site, Milwaukee
Research Site, Holon
Research Site, Oaxaca City
Research Site, Ẕerifin
Research Site, Covington
Research Site, Bedford
Research Site, Houston
Research Site, Aurora
Research Site, Littleton
Research Site, Napoli
Research Site, Jerusalem
Research Site, San Francisco
Research Site, Sacramento
Research Site, Springfield
Research Site, Messina
Research Site, Petah Tikva
Research Site, Tel Aviv
Research Site, Rehovot
Research Site, Jerusalem
Research Site, Hartford
Research Site, Berazategui
Research Site, CABA
Research Site, Ciudad de Buenos Aires
Research Site, La Plata
Research Site, San Miguel de Tucumán
Research Site, Ijuí
Research Site, Passo Fundo
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, Rio de Janeiro
Research Site, São José do Rio Preto
Research Site, São Paulo
Research Site, São Paulo
Research Site, Toronto
Research Site, Toronto
Research Site, Montreal
Research Site, Hradec Králové
Research Site, Ostrava-Poruba
Research Site, Prague
Research Site, Zlín
Research Site, Roma
Research Site, Roma
Research Site, México
Research Site, Gdansk
Research Site, Grzepnica
Research Site, Lodz
Research Site, Lublin
Research Site, Olsztyn
Research Site, Poznan
Research Site, Warsaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Lead Sponsor
Myriad Genetic Laboratories, Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
AstraZeneca
INDUSTRY